Quantitative analysis via ultra-performance liquid chromatography revealed the following constituent profile: Parishin A (PA, 6.11%), Parishin B (PB, 3.10%), Parishin C (PC, 0.57%), Parishin E (PE, 3.44%), gastrodin (GAS, 1.28%), S-(4-hydroxybenzyl) glutathione (4-HBG, 0.60%), and 4-hydroxybenzyl alcohol (HBA, 0.77%)
Micro-wins come about when micro-habits lead to better health, he continues
For some, perimenopause or other hormonal shifts are part of the equation, too
In cases of confirmed, severe gastroparesis attributable to GLP-1 therapy, medication discontinuation is generally recommended, consistent with FDA labeling that these agents are not recommended for patients with severe gastroparesis
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
doi: 10.1016/s0092-8674(00)80434-1